Abstract 251P
Background
Uterine leiomyoma (UL) is the most common female pelvic benign tumor with recurrence rates of 16.7%-52.8%. We aimed to propose a prognostic index (PI) model for predicting the long-term (>5 years) risk of UL recurrence.
Methods
Women aged 18–44 years who initially underwent myomectomy for UL at one of the three study hospitals between April 2012 and October 2013 were enrolled. The data collected included patients’ demographics, leiomyomas’ characteristics, relapses, subsequent contraceptive methods, and postoperative gravidity and parity. A PI model was proposed based on the β-coefficients in the results of multivariate Cox regression analysis in prediction model group. The differences among the PI-based risk groups were tested by Kaplan–Meier analysis (using paired log-rank test) and univariate Cox regression analysis (using the Forward: LR) in prediction model, internal validation and external validation group.
Results
There were 725 patients included in this study. PI formula =1.5(if 3-5 leiomyomas)+2(if > 5 leiomyomas)+1(if residue)+1(if not submucosal)+1(if combined endometriosis). The PI value (0-5) was divided into low-risk group, intermediate-risk group, and high-risk group by cut-off values 1.25 and 3.75. In the prediction model group, the high-risk group had a significantly 4.55 times greater recurrence risk of UL than that in the low-risk group [cumulative recurrence rate (CR): 82.1% vs 29.5%, HR = 4.55, 95% CI; 2.821-7.339]; the intermediate-risk group had a significantly 2.81 times greater recurrence risk of UL than that in the low-risk group (CR: 62.3% vs 29.5%, HR = 2.81, 95% CI; 2.035-3.878). The differences between any two risk groups were also statistically significant (P < 0.05) in both internal and external validation groups.
Conclusions
The PI model was proved to be effective in distinguishing low-risk, intermediate-risk, and high-risk groups for long-term recurrence of UL after initial myomectomy in women aged 18-44 years, allowing it to be an objective tool aid in clinical decision making. In the future, prospective researches should be carried out to confirm the predictive ability of this PI model, and its practical value in clinical decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zheng Yu Li.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract